189 related articles for article (PubMed ID: 32735623)
21. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
[TBL] [Abstract][Full Text] [Related]
23. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
[TBL] [Abstract][Full Text] [Related]
24. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
25. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
26. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Xiao L; Amlashi FG; Elimova E; Blum Murphy MA; Sanders E; Shanbhag N; Thomas I; Ajani JA
Oncology; 2019; 96(5):252-258. PubMed ID: 30893708
[TBL] [Abstract][Full Text] [Related]
27. Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
Otsuka R; Iwasa S; Yanai T; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Hashimoto H; Sekiguchi M; Makino Y; Boku N; Yamaguchi M
Int J Clin Oncol; 2020 Apr; 25(4):595-601. PubMed ID: 31853798
[TBL] [Abstract][Full Text] [Related]
28. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
29. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
[TBL] [Abstract][Full Text] [Related]
32. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
33. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Fanotto V; Fornaro L; Bordonaro R; Rosati G; Rimassa L; Di Donato S; Santini D; Tomasello G; Leone F; Silvestris N; Stragliotto S; Scartozzi M; Giampieri R; Nichetti F; Antonuzzo L; Cinieri S; Avallone A; Pellegrino A; Melisi D; Vasile E; Gerratana L; Aprile G
J Geriatr Oncol; 2019 Jul; 10(4):591-597. PubMed ID: 30551958
[TBL] [Abstract][Full Text] [Related]
34. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
35. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
Saito S; Muneoka Y; Ishikawa T; Akazawa K
Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.
Fanotto V; Uccello M; Pecora I; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Ferrari L; Bordonaro R; Vivaldi C; Gerratana L; Bozzarelli S; Filippi R; Bilancia D; Russano M; Aprile G
Oncologist; 2017 Dec; 22(12):1463-1469. PubMed ID: 28860412
[TBL] [Abstract][Full Text] [Related]
39. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
40. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Jimenez-Fonseca P; Carmona-Bayonas A; Martínez de Castro E; Custodio A; Pericay Pijaume C; Hernandez R; Aguado G; Castro Unanua N; Cano JM; López F; Garrido M; Fernández Montes A; Visa L; Sánchez Cánovas M; Limón ML; Martínez Lago N; Pimentel P; Hurtado A; Azkárate A; Longo F; Diez M; Arias-Martinez A; Sauri T; Martín Carnicero A; Mangas M; Martín Richard M; Granja M; Ramchandani A; Hernández Pérez C; Cerdá P; Gil-Negrete A; Calvo M; Vidal Tocino R; Gallego J
Gastric Cancer; 2021 Mar; 24(2):445-456. PubMed ID: 32970266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
